Alto Neuroscience, Inc. (NYSE:ANRO) Sees Significant Increase in Short Interest

Alto Neuroscience, Inc. (NYSE:ANRO) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 5,350,000 shares, an increase of 29.9% from the September 30th total of 4,120,000 shares. Based on an average trading volume of 656,800 shares, the days-to-cover ratio is currently 8.1 days. Approximately 24.1% of the company’s shares are short sold.

Alto Neuroscience Stock Up 5.8 %

ANRO opened at $4.37 on Monday. Alto Neuroscience has a 12 month low of $3.93 and a 12 month high of $24.00. The firm’s fifty day simple moving average is $12.02 and its 200 day simple moving average is $12.33. The company has a quick ratio of 19.85, a current ratio of 19.85 and a debt-to-equity ratio of 0.04.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.07. On average, research analysts expect that Alto Neuroscience will post -2.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ANRO. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Rodman & Renshaw cut shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. RODMAN&RENSHAW cut shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Robert W. Baird reduced their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, Wedbush cut shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and an average target price of $24.40.

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in ANRO. Vanguard Group Inc. acquired a new stake in Alto Neuroscience in the 1st quarter valued at $8,233,000. Price T Rowe Associates Inc. MD acquired a new stake in Alto Neuroscience in the 1st quarter valued at $9,788,000. Jennison Associates LLC acquired a new stake in Alto Neuroscience in the 1st quarter valued at $7,039,000. Bowie Capital Management LLC acquired a new stake in Alto Neuroscience in the 2nd quarter valued at $462,000. Finally, TD Asset Management Inc acquired a new stake in Alto Neuroscience in the 2nd quarter valued at $928,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.